This week's Fierce Biotech is brought to you by Lonza.

Whitepaper: Antibody Drug Conjugates in Oncology: How Technology Advances Can Streamline Development and Manufacturing

Antibody-drug conjugates (ADCs) are transforming oncology, with commercial sales projected to surpass $30 billion by 2030. Breakthroughs in ADC technology are enhancing efficacy and safety, while streamlining development and manufacturing processes. This exclusive whitepaper reveals:

• The dynamic growth of the ADC oncology market.
• Innovations in bioconjugation technology.
• Lonza's end-to-end solutions for ADC manufacturing and lifecycle management.

Don’t miss your chance to gain actionable insights and stay ahead in this rapidly evolving market. Access expert-driven strategies to streamline your ADC pipeline and accelerate oncology breakthroughs.